Aflac Inc.

ticker: AFL step: 01 generated: 2026-05-12 source: quick-research

Aflac Incorporated (AFL) — Business Overview

Business Description

Aflac is the #1 supplemental insurance company in the United States and a leading supplemental health/life insurer in Japan. Founded 1955 in Columbus, Georgia. Pioneered cancer insurance in 1958. Two operating segments: Aflac Japan (~70% revenue, focus on cancer + medical insurance) and Aflac U.S. (supplemental health products including accident, disability, dental, vision, hospital indemnity). Branding hallmark: "Aflac duck" mascot.

Revenue Model

~$17.2B FY2025 revenue (down 9.3% from $18.9B in 2024) — declined due to net investment losses. Premium revenue (net earned premiums) + net investment income. Predominantly Japan: Aflac Japan generates ~70% of premium income. Lump-sum benefits paid directly to policyholders (not providers) — distinctive market positioning. Highly profitable (~22% ROE).

Products & Services

• Cancer insurance — Aflac's heritage franchise (pioneered 1958)
• Medical insurance — Japan focus (long-term)
• Accident insurance — US workplace voluntary benefit
• Disability insurance — Short + long-term
• Dental + Vision — US workplace
• Hospital indemnity — US
• Long-Term Care — New hybrid LTC rider launched 2025-26
• Medical Shield — New product rollout
• Aflac Re Bermuda — Reinsurance subsidiary (Japan Post deal 2026)

Customer Base & Go-to-Market

500,000+ independent insurance agents + brokers globally. ~90,000 employer partnerships in US providing supplemental group insurance. Heritage individual + workplace voluntary. Geographic: ~70% Japan + ~30% US. Aging Japanese population + younger US workplace = different demand dynamics.

Competitive Position

#1 US supplemental insurance. Japan's largest cancer insurer. Competes with MetLife, Prudential, AIG, Sun Life, Lincoln Financial, Unum (US); Sony Life, Tokio Marine (Japan). Differentiated by: distinctive brand (Aflac duck), lump-sum payments to policyholders, dual-market scale (US + Japan), supplemental specialty rather than core medical.

Key Facts

• Founded: 1955 (Columbus, GA, by Amos brothers)
• Headquarters: Columbus, GA
• Employees: ~12,000+
• Exchange: NYSE (AFL)
• Sector / Industry: Financials / Insurance (Life & Health)
• Market Cap: ~$60B
• CEO: Daniel Amos (since 1990, founder's nephew); Chairman
• Long-tenured CEO = 35+ years

ticker: AFL step: 04 generated: 2026-05-12 source: quick-research

Aflac Incorporated (AFL) — Financial Snapshot

Income Statement Summary

Note: FY25 net earnings $3.6B reflects net investment losses + increased credit loss allowances. Q4 25 diluted EPS $2.64. Q3 25 annualized adjusted ROE ex-FX = 22.1% — strong core profitability.

Cash Flow & Balance Sheet (FY2025)

Key Ratios (approximate)

• P/E: ~16x | P/B: ~1.7x
• Revenue Growth (TTM): -9.3% | Net Margin: 21.2%
• Dividend Yield: ~2.0% | Dividend Growth: 43 years
• $3.5B 2025 buybacks (~6% of market cap)
• 114.3M shares remaining authorized for repurchase

Growth Profile

Japan core earned premiums declining 1-2% (paid-up products + aging population). US supplemental growing low-single-digit. Investment income compounding as portfolio rolls forward. Margin recovery on credit loss normalization. Hybrid LTC rider + Medical Shield new product rollouts. Aflac Re Bermuda + Japan Post deal expand reinsurance optionality.

Forward Estimates

• FY 2026: Adj EPS ~$7.00-7.50; net premium income +0-1%; ROE ~15-18%
• FY 2027: Adj EPS ~$7.50-8.00 with new product traction
• $113 average analyst price target vs ~$103 = ~10% upside
• 43-year dividend growth track record + 5.2% Q1 26 dividend increase

ticker: AFL step: 12 generated: 2026-05-12 source: quick-research

Aflac Incorporated (AFL) — Investment Catalysts & Risks

Bull Case Drivers

1. 22% ROE + 43-year dividend growth + $3.5B annual buybacks — Q3 2025 annualized adjusted ROE ex-FX = 22.1%. Best-in-class insurance profitability. 43 consecutive years of dividend increases (Dividend Aristocrat). 5.2% Q1 26 dividend increase. $3.5B 2025 buybacks (~6% of market cap). 114M shares remaining authorized = continued capital return.

2. Dual-market diversification: 70% Japan + 30% US — Aflac generates ~70% revenue from Japan (largest cancer insurer + brand leader) + 30% US (largest supplemental). US growth offsets Japan demographic decline. Distinctive lump-sum payment model + Aflac duck branding creates moat. Aflac Re Bermuda reinsurance optionality (Japan Post deal 2026).

3. New product rollouts: Hybrid LTC + Medical Shield — Hybrid Long-Term Care rider (combines life + LTC) addresses major US market gap. Medical Shield rollout expanding US coverage. Higher tech + distribution spending (some margin pressure) but positions for future growth as insurance market evolves toward simpler supplemental products.

4. Cash flow conversion + balance sheet quality — Nearly all operating cash flow converts to free cash flow → substantial returns via buybacks + debt repayment. ~$110B investment portfolio. Yen hedging program protects economic value. Conservative balance sheet supports continued capital return through cycles.

Bear Case Risks

1. Japan demographic decline = structural premium pressure — Japan's population aging faster than anywhere else; expected to lose 34% by end of century. Japan core earned premiums guided to decline 1-2% in 2026. Older policyholders age out of new product purchases. Insurance demand structurally challenged in Japan despite incumbent leadership.

2. 2025 net margin compressed 28.8% → 21.2% — Net profit margin moved from 28.8% to 21.2% over the last year. Higher tech + distribution spending not yet translating into margin expansion. Credit loss allowances on investment portfolio increased. If credit cycle worsens, margins compress further.

3. Yen/USD currency volatility + interest rate sensitivity — Every 5 yen to dollar move = ~$0.07 EPS impact. ~70% of business in yen-denominated terms. If yen strengthens materially, USD-reported earnings compress. Enterprise hedging program mitigates but doesn't eliminate. Plus interest rate sensitivity on investment portfolio.

4. Cybersecurity + tech execution risk — Massive cyberattack in early 2026 raised concerns. Insurance industry highly targeted. Customer data + claim systems disruption risk. Multi-year tech investment program needed but execution complexity high.

Upcoming Events

• Q2 2026 earnings (August 2026) — Hybrid LTC + Medical Shield traction
• Q3 2026 earnings (November 2026) — Mid-year guide reset
• Aflac Re Bermuda + Japan Post integration — Reinsurance optionality
• Yen/USD evolution — Direct EPS driver
• Federal Reserve + BoJ rate policy — Investment income driver

Analyst Sentiment

Sell-side consensus is Hold / Market Perform with average price target ~$113 vs. recent ~$103 trading levels (~10% upside). Keefe, Bruyette & Woods reinstated Market Perform $113. Bulls cite 22% ROE + 43-yr dividend growth + buybacks + dual-market diversification + new products. Bears focus on Japan demographic + margin compression + yen risk + cyberattack. AFL is widely viewed as a high-quality compounder with structural Japan headwinds + steady capital return.

Research Date

Generated: 2026-05-12